Financing
Proceeds from lines of credit
Moderna Proceeds from lines of credit remained flat by 0.0% to $150.00M in Q4 2025 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementCash Flow Statement
SectionFinancing
CategoryLiquidity
SignalLower is better
VolatilityVolatile
First reportedQ1 2023
Last reportedQ4 2025Feb 20, 2026
How to read this metric
High usage may indicate a need for working capital or temporary liquidity constraints, while low usage suggests strong internal cash generation.
Detailed definition
Cash inflows generated by drawing down on revolving credit facilities or other short-term debt instruments. This represe...
Peer comparison
Commonly used by companies to bridge timing gaps in cash flow cycles.
Metric ID:
amd_proceeds_from_lines_of_creditHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $0.00 | $0.00 | $600.00M |
Range$0.00 – $600.00M
Proceeds from lines of credit at Other Companies
Frequently Asked Questions
- What is Moderna's proceeds from lines of credit?
- Moderna (MRNA) reported proceeds from lines of credit of $150.00M in Q4 2025.
- What does proceeds from lines of credit mean?
- Cash received from borrowing against a line of credit.